Stockscreener 앱 받기
0.9481
11.57%
-0.1219
전일 마감가:
$1.07
열려 있는:
$0.9889
하루 거래량:
1.57M
Relative Volume:
1.43
시가총액:
$94.81M
수익:
$1.63M
순이익/손실:
$-40.95M
주가수익비율:
-1.6154
EPS:
-0.5869
순현금흐름:
$-18.80M
1주 성능:
+6.99%
1개월 성능:
+0.78%
6개월 성능:
-41.59%
1년 성능:
+53.40%
1일 변동 폭
$0.92
$0.9894
1주일 범위
$0.8901
$1.12
52주 변동 폭
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
명칭
Rani Therapeutics Holdings Inc
전화
(408) 457-3700
주소
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.9489 | 106.91M | 1.63M | -40.95M | -18.80M | -0.5869 |
VRTX
Vertex Pharmaceuticals Inc
|
436.73 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
636.71 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.12 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.56 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.84 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Lake Street | Buy |
| 2024-08-02 | 개시 | Oppenheimer | Outperform |
| 2024-06-14 | 개시 | Maxim Group | Buy |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-07-27 | 개시 | H.C. Wainwright | Buy |
| 2022-06-13 | 개시 | Wedbush | Outperform |
모두보기
Rani Therapeutics Holdings Inc 주식(RANI)의 최신 뉴스
Rani Therapeutics raises $20 million in direct offering - Investing.com
Rani Therapeutics to raise $20M in registered direct offering - MSN
Sovereign wealth fund leads $20M raise for oral drug delivery firm - Stock Titan
Rani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14 - MSN
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Rani Therapeutics Price Target Maintained With a $5.00/Share by Canaccord Genuity - Moomoo
Rani Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
RANI Maintained by Canaccord Genuity -- Price Target Stays at $5 - GuruFocus
Canaccord reiterates Buy on Rani Therapeutics stock, $5 target - Investing.com
Canaccord reiterates Buy on Rani Therapeutics stock, $5 target By Investing.com - Investing.com Canada
Insiders Enjoy US$582k Return After Buying Rani Therapeutics Holdings Stock - simplywall.st
Lake Street Initiates Rani Therapeutics(RANI.US) With Buy Rating, Announces Target Price $9 - Moomoo
Rani Therapeutics CFO Sanford to depart - MSN
Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price - TipRanks
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition - The Manila Times
Rani Therapeutics Q1 Net Loss Narrows, Revenue Rises; CFO Svai Sanford to Step Down - Moomoo
RANI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Rani Therapeutics reports Q1 EPS (4c), consensus (5c) - TipRanks
Rani Therapeutics Sees Funding Sufficient Into 4Q27 >RANI - Moomoo
Rani Therapeutics CFO to depart, reports Q1 results - Investing.com UK
Rani Therapeutics CFO to depart, reports Q1 results By Investing.com - Investing.com South Africa
Rani Therapeutics Faces Nasdaq Bid Price Noncompliance Notice - TipRanks
Rani Therapeutics Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
RANI: Q1 2026 saw clinical progress, leadership changes, and a reduced net loss year-over-year - TradingView
Rani Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Rani Therapeutics (RANI) posts Q1 2026 loss with new Chugai revenue and $43M cash - Stock Titan
Nasdaq warns Rani Therapeutics (NASDAQ: RANI) as CFO plans transition - Stock Titan
Oral biologics firm Rani trims Q1 loss; CFO to step down - Stock Titan
Rani Therapeutics Reports First Quarter 2026 Financial - GlobeNewswire
SymBiosis Capital holds 4.43M RANI shares, reports 4.4% stake (RANI) - Stock Titan
TradingKey - TradingKey
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference - The Manila Times
Rani Therapeutics (NASDAQ:RANI) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Rani Therapeutics Holdings Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
This Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last Year - Yahoo Finance
MSN Money - MSN
Rani Therapeutics (RANI) Projected to Post Earnings on Wednesday - MarketBeat
RANI Technical Analysis | Trend, Signals & Chart Patterns | RANI THERAPEUTICS HOLDINGS-A (NASDAQ:RANI) - ChartMill
RANI Price Today: Rani Therapeutics Holdings, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Rani Therapeutics | SCHEDULE 13G: Others - Moomoo
Vanguard Capital Management takes 5.12% stake in Rani Therapeutics (RANI) - Stock Titan
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Rani Therapeutics Holdings (RANI) price target decreased by 13.51% to 8.16 - MSN
Form DEF 14AOther definitive proxy statements - ADVFN
Rani Therapeutics Holdings Inc (RANI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rani Therapeutics Holdings Inc 주식 (RANI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| South Cone Investments Limited | 10% Owner |
Oct 21 '25 |
Sale |
2.77 |
4,000,000 |
11,074,000 |
2,379,194 |
| South Cone Investments Limited | 10% Owner |
Oct 20 '25 |
Sale |
2.41 |
1,923,000 |
4,637,314 |
6,379,194 |
2.25%
0.46%
자본화:
|
볼륨(24시간):